Several PROTACs are developed to target cancer drivers like the androgen receptor (AR) and estrogen receptor (ER), and they have entered phase I/II clinical trials for metastatic prostate and breast cancer, respectively, showing encouraging signs of target degradation and clinical activity. This evidence concerns the gene AR and breast carcinoma.